FDA approves generic Metrogel Gel from Alembic’s Aleor Dermaceuticals
The product had an estimated $29 million U.S. market size for the year ended June 2021, according to data from IQVIA.
Alembic Pharmaceuticals’ joint venture, Aleor Dermaceuticals, has received approval from the Food and Drug Administration for its generic Metrogel Gel (metronidazole gel, 1%).
The topical gel is indicated for the topical treatment of inflammatory rosacea lesions. The full approval follows the company having received a tentative approval from the agency previously.
[Read more: Alembic launches generic Sinequan]
The product had an estimated $29 million U.S. market size for the year ended June 2021, ac-cording to data from IQVIA.
Alembic said that it has received a total of 149 approved generics, including 132 final approvals and 17 tentative approvals from the FDA.